Common use of Market Share Clause in Contracts

Market Share. As an adjunct to Sections 1-8 and including any additional assumptions, demonstrate the impact on market share as a result of the PLA Submission. Projected Market in Alberta as a Result of the PLA Terms (% Market Share) • List projected market shares as total number of patients and percentage of total market for each disease state/indication resulting from the PLA Submission. • Market shares for years one, two and three must be reported for a full calendar year. • State where the proposed market is coming from (e.g., new patients, cannibalization of another product’s market share). Incremental Change in Market in Alberta as a Result of the PLA Submission (% Market Share) • Indicate the net change in market share from the original BIA as a result of the PLA Submission. • As an adjunct to Sections 1-9 and including any additional assumptions, demonstrate the impact on pharmacy program costs as a result of the PLA Submission. Direct drug costs to the Alberta Health and Wellness sponsored drug programs as a Result of the PLA Terms • Calculate the direct prescription costs that the Government-Sponsored Drug Plans would incur as a result of the PLA Submission. • Prescription costs should be an extension of the prevalence of the disease state/indication, the projected market share of the product and the prescription costs to the Government-Sponsored Drug Plans as calculated in Section 3. Incremental Direct drug to the Alberta Health and Wellness sponsored drug programs as a Result of the PLA Terms • Calculate the incremental change in direct prescription costs from outlined in Sections 1-9 that the Alberta Health and Wellness sponsored drug benefit programs would incur as a result of the PLA offer • Calculate relevant one-way and/or multi-way sensitivity analyses for direct prescription costs and incremental prescription cost changes outlined in Sections 1-9 as a result of the PLA offer.

Market Share.  As an adjunct to Sections 1-8 and including any additional assumptions, demonstrate the impact on market share as a result of the PLA Submission. Projected Market Project (% Mark ed Mar et Sha ket in Alberta as re) a Result of the th e PLA Terms (% Market Share) •  List projected market shares as total number of patients and percentage of total market for each disease dise state/indication resulting from the PLA Submission. •  Market shares for years one, two and three must be reported for a full calendar year. •  State market where the proposed prop share). osed market is coming co ming from (e.g.e.g ., new patients, cannibalization of another productprodu ase ct’s market share). Incremental Change in Market in Alberta as a Result of the PLA Submission (% Market Share) •  Indicate the net change in market share from the original BIA as a result of the PLA Submission. •  As an adjunct to Sections 1-9 and including any additional assumptions, demonstrate the impact on pharmacy program costs as a result of the PLA Submission. Direct drug  Calculate the direct prescription costs to the that Alberta Health and Wellness sponsored drug programs as a Result of the PLA Terms • Calculate the direct prescription costs that the Government-Sponsored Drug Plans plans would incur as a result of the PLA Submission. •  Prescription costs should be an extension of the prevalence of the disease state/indication, the projected market share of the product and the prescription costs to the Government-Sponsored Drug Plans Alberta Health and Wellness sponsored drug plans as calculated in Section 3. Incremental Direct Increme drug pro ntal D grams irect drug to the Alberta Health and Wellness sponsored drug programs as a Result of Alberta Health the PLA Terms • and Wellness sponsored  Calculate the incremental change in direct prescription costs from outlined in Sections 1-9 that the Alberta Health and Wellness sponsored drug benefit programs would incur as a result of the PLA offer •  Calculate relevant one-way and/or multi-way sensitivity analyses for direct prescription costs and incremental prescription cost changes outlined in Sections 1-9 as a result of the PLA offer.